Generex Biotechnology's Cash & cash equivalent grew by 181.03 % in the Q3 2021 sequentially, faster than Current Liabilities, this led to improvement in Generex Biotechnology's Quick Ratio to 0.03, Quick Ratio remained below Generex Biotechnology Corp average.

Within Major Pharmaceutical Preparations industry 553 other companies have achieved higher Quick Ratio than Generex Biotechnology in third quarter 2021. While Quick Ratio total ranking in the third quarter 2021 has deteriorated compared to the prior quarter from 4767 to 5220.

Explain Quick Ratio?
How much Cash & cash equivalents GNBT�s has?
What are GNBT�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GNBT Quick Ratio	(Apr 30 2021) Q3	(Jan 31 2021) Q2	(Oct 31 2020) Q1	(Jul 31 2020) Q4	(Apr 30 2020) Q3
Y / Y Current Liabilities Change	61.34 %	58.92 %	113.4 %	80.44 %	-33.57 %
Y / Y Cash & cash equivalent Change	302.03 %	121.52 %	179.27 %	-98.9 %	-82.45 %
Quick Ratio MRQ	0.03	0.01	0.02	0	0.01
GNBT's Total Ranking	# 5220	# 4767	# 5325	# 5568	# 5390
Seq. Current Liabilities Change	7.35 %	13.81 %	0.78 %	31.03 %	5.74 %
Seq. Cash & cash equivalent Change	181.03 %	-28.5 %	5294.55 %	-96.29 %	54.85 %

Quick Ratio third quarter 2021 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 554
Healthcare Sector	# 1090
Overall Market	# 5220

Quick Ratio Statistics
High	Average	Low
0.51	0.09	0
(Apr 30 2014)		(Jul 31 2020)

Financial Statements
Generex Biotechnology's Current Liabilities	$ 64 Millions	Visit GNBT's Balance sheet
Generex Biotechnology's Cash & cash equivalent	$ 2 Millions	Visit GNBT's Balance sheet
Source of GNBT's Sales		Visit GNBT's Sales by Geography

Cumulative Generex Biotechnology's Quick Ratio

GNBT's Quick Ratio for the trailling 12 Months

GNBT Quick Ratio	(Apr 30 2021) 12 Months	(Jan 31 2021) 12 Months	(Oct 31 2020) 12 Months	(Jul 31 2020) 12 Months	(Apr 30 2020) 12 Months
Y / Y Current Liabilities TTM Growth	74.65 %	35.24 %	16.4 %	-1.86 %	-14.59 %
Y / Y Cash & cash equivalent TTM Growth	30.44 %	-57.19 %	-76.18 %	-86.1 %	-67.46 %
Quick Ratio TTM	0.01	0.01	0.01	0.01	0.02
Total Ranking TTM	# 5095	# 4466	# 5098	# 5106	# 5114
Seq. Current Liabilities TTM Growth	11.95 %	12.18 %	18.11 %	17.75 %	-13.31 %
Seq. Cash & cash equivalent TTM Growth	67.59 %	21.3 %	53.53 %	-58.21 %	-45 %

Quick ratio ranking by company, industry and sector >> Back to GNBT Financial Strength Comparisons >> Go to Compare GNBT Quick Ratio to its Competitors

On the trailing twelve months basis In Spite of the rise in Current Liabilities in the Q3 2021 to $64.07 millions, cumulative Quick Ratio remained unchanged at 0.01 below the Generex Biotechnology Corp average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 529 other companies have achieved higher Quick Ratio than Generex Biotechnology. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2020 from 4466 to 5095.

Explain Quick Ratio?
How much Cash & cash equivalents GNBT�s has?
What are GNBT�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 530
Healthcare Sector	# 1037
Within the Market	# 5095

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.07	0.03	0.01
(Jan 31 2018)		(Apr 30 2017)

Companies with similar Quick Ratio in the quarter ending Apr 30 2021, within Major Pharmaceutical Preparations Industry	Quick Ratio	Apr 30 2021 MRQ Cash & cash equivalent	Apr 30 2021 MRQ Current Liabilities
Sunwin Stevia International Inc.	0.07	$ 1.566 Millions	$ 23.940 Millions
Oncotelic Therapeutics Inc	0.06	$ 0.831 Millions	$ 13.026 Millions
Organon and Co	0.05	$ 141.000 Millions	$ 2,875.000 Millions
China Pharma Holdings Inc	0.05	$ 0.535 Millions	$ 11.030 Millions
Wellness Center Usa Inc	0.05	$ 0.146 Millions	$ 3.101 Millions
Reshape Lifesciences Inc	0.04	$ 0.896 Millions	$ 20.922 Millions
Bioxytran Inc	0.03	$ 0.092 Millions	$ 2.878 Millions
Lifecore Biomedical Inc	0.03	$ 2.248 Millions	$ 73.119 Millions
Intellipharmaceutics International Inc	0.03	$ 0.203 Millions	$ 6.908 Millions
Generex Biotechnology Corp	0.03	$ 1.675 Millions	$ 64.074 Millions
Rebus Holdings Inc	0.03	$ 0.758 Millions	$ 30.097 Millions
Bioadaptives Inc	0.02	$ 0.028 Millions	$ 1.165 Millions
Northwest Biotherapeutics Inc	0.02	$ 7.468 Millions	$ 363.409 Millions
Musclepharm Corporation	0.02	$ 0.592 Millions	$ 29.104 Millions
American Bio Medica Corporation	0.02	$ 0.063 Millions	$ 3.167 Millions
REGENEREX PHARMA, INC.	0.02	$ 0.007 Millions	$ 0.419 Millions
Nanomix Corp	0.02	$ 0.047 Millions	$ 3.049 Millions
Sangui Biotech International Inc	0.01	$ 0.012 Millions	$ 0.952 Millions
Actavia Life Sciences Inc	0.01	$ 0.032 Millions	$ 2.897 Millions
Provectus Biopharmaceuticals Inc	0.01	$ 0.350 Millions	$ 32.365 Millions
Innovation1 Biotech Inc	0.01	$ 0.025 Millions	$ 2.521 Millions
Novaccess Global Inc	0.01	$ 0.022 Millions	$ 2.614 Millions
Integrated Biopharma Inc	0.01	$ 0.105 Millions	$ 14.372 Millions
Ainos Inc	0.01	$ 0.009 Millions	$ 1.500 Millions
Celularity Inc	0.01	$ 0.029 Millions	$ 5.040 Millions

Date modified: 2026-09-08T15:10:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.